Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
about
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the prevention and treatment of postmenopausal osteoporosisEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenFRAX and the assessment of fracture probability in men and women from the UKOsteoporosis and its managementIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchOsteoporosis Treatment: When to Discontinue and When to Re-startPostmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisTreatment of primary osteoporosis in menAn overview on the treatment of postmenopausal osteoporosisThe epidemiology and management of postmenopausal osteoporosis: a viewpoint from BrazilBisphosphonates: from bench to bedsideUpdate on bazedoxifene: a novel selective estrogen receptor modulatorOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataComparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness.The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium.Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials.Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics.Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?Calcium citrate and vitamin D in the treatment of osteoporosis.Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.Prevention of hip fractures in long-term care: relevance of community-derived data.Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.UK clinical guideline for the prevention and treatment of osteoporosisEfficiency of Balloon Kyphoplasty in the Treatment of Osteoporotic Vertebral Compression FracturesImproving osteoporosis care in high-risk home health patients through a high-intensity interventionSkeletal effects of zoledronic acid in an animal model of chronic kidney diseaseDo bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.Preventing fractures in elderly people.Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesVertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study
P2860
Q24242674-17CD514D-6235-4298-B6A8-9DBC30CAE418Q24245000-D3486FC2-6622-43BA-B8B3-3BC3236980C1Q24612411-EECCE6FA-D743-4F87-8402-6DF97A9735AFQ24654123-2A9403EC-1104-4F76-8DF6-F088E57EEC96Q24670075-57F420E3-EF69-4FF5-8435-3C26E5359C00Q24680238-D7B1CC4A-BFC5-46D8-A76E-50ED3F4012FDQ24802074-23474FC3-E428-40F8-AFED-EC15584F493FQ26782621-15D81F2A-AE07-4B3D-BE0A-E07B1748BF3DQ26858980-34EE6FDF-20F8-4AB3-B045-812613F0EAFDQ26864207-347F5635-C1BF-44C7-92B5-B45A17D6A516Q26864549-522259AE-631D-4F82-BB52-1828F7F0703FQ26991748-41B4B98D-E442-485A-90E4-EC603169CE0DQ27013070-21C43AEB-BCF2-4978-8398-8FB3AC811808Q28080673-86D383FC-829C-4F4A-894C-44648E2CBDF3Q28251212-B444BEE2-B32B-4673-82AC-7A9E3D343575Q28258998-7E6E1B95-92B5-44A0-8AA6-009B6FF253F0Q30235173-5FDFA465-99E6-4D80-B2B2-D0F001DD9427Q30577427-CBC8E019-1D1C-4D31-96F7-6B0DFC710077Q30819137-83F4ABA3-1A2E-4799-A1D2-3AD8CAAAB592Q30967433-D46D82ED-F9D1-4AE3-BA28-94A5B00E8286Q30992843-3E7BD94D-40DF-422A-A2EB-57CC36FFAED3Q31141287-0D0E82F7-FEF5-4840-867A-8189E04F05D4Q31145542-C91B295C-4D9E-46E8-8446-53824353F599Q31162221-F073C6C1-0363-490A-934C-07CB98ED8861Q31795247-F80D2C92-1756-4336-84AA-ECABC7402826Q33194319-27FC8011-0192-439D-BAFB-8A8FF0F6354CQ33305959-29B8DB21-96DD-4388-8D78-8B7C6DE87BD3Q33416959-8576F30D-56C9-4AD7-B134-1E95B470B42AQ33449783-2E4DD01C-9364-44A0-9F55-01043BE1543DQ33482516-C1BFE198-A00E-47AD-AE7E-A7D6A1283F92Q33546626-E3969965-6A70-4B5D-ABD0-BA0A758CA015Q33569806-EA823E1A-EC0B-48D7-A571-416B59EEC8DAQ33581078-DCD2D4DF-33D3-4623-8B46-CA0A4C224D6FQ33657555-940C811F-8541-4703-8FB6-02BE05622B50Q33710755-2F4BDF12-8F8E-4A3B-B9A6-574F15842F53Q33779709-00C93F7F-6907-446B-AC5C-91FD0FB7F8F0Q33788945-3D3475B2-8337-4ABF-9203-629B8C64F215Q33815676-7AFE8C6D-3502-4674-8AF2-BC88E8F2FD9FQ33819111-0955D459-44DD-4DC4-BB13-5D47A310364FQ33873961-8DEF6551-4689-476E-B2A8-A8CC900E5B01
P2860
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Randomized trial of the effect ...... te Therapy (VERT) Study Group.
@en
Randomized trial of the effect ...... icacy with Risedronate Therapy
@nl
type
label
Randomized trial of the effect ...... te Therapy (VERT) Study Group.
@en
Randomized trial of the effect ...... icacy with Risedronate Therapy
@nl
prefLabel
Randomized trial of the effect ...... te Therapy (VERT) Study Group.
@en
Randomized trial of the effect ...... icacy with Risedronate Therapy
@nl
P2093
P356
P1476
Randomized trial of the effect ...... ate Therapy (VERT) Study Group
@en
P2093
Reginster J
Roumagnac I
Sorensen OH
P2888
P356
10.1007/S001980050010
P407
P577
2000-01-01T00:00:00Z